Indaptus Therapeutics
INDP
30 hedge funds and large institutions have $90.1M invested in Indaptus Therapeutics in 2018 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 2 increasing their positions, 13 reducing their positions, and 6 closing their positions.
312% more call options, than puts
Call options by funds: $313K | Put options by funds: $76K
83% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 6
25% more capital invested
Capital invested by funds: $72.2M → $90.1M (+$17.9M)
20% more funds holding
Funds holding: 25 → 30 (+5)
85% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 13
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EIM
Essex Investment Management
Boston,
Massachusetts
|
+$2.4M |
| 2 |
PCM
Prelude Capital Management
New York
|
+$723K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$327K |
| 4 |
BFM
Boothbay Fund Management
New York
|
+$273K |
| 5 |
Simplex Trading
Chicago,
Illinois
|
+$273K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PM
Prosight Management
Dallas,
Texas
|
-$4.02M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$1.98M |
| 3 |
LCM
Laurion Capital Management
New York
|
-$532K |
| 4 |
EDRH
Edmond de Rothschild Holding
Chambesy,
Switzerland
|
-$491K |
| 5 |
MIH
Meitav Investment House
Bene-Beraq,
Israel
|
-$491K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AS
26
Altshuler Shaham
Tel Aviv,
Israel
| $47K | -$368K | -27 | -90% |
|
|
LTFS
27
Ladenburg Thalmann Financial Services
Miami,
Florida
| $38K | +$27.3K | +2 | New |
|
|
RFA
28
Reilly Financial Advisors
La Mesa,
California
| $38K | +$27.3K | +2 | New |
|
|
PWM
29
PRW Wealth Management
Quincy,
Massachusetts
| $29K | +$27.3K | +2 | New |
|
|
RE
30
RBC Europe
London,
United Kingdom
| $13.3K | +$13.6K | +1 | New |
|
31
Wells Fargo
San Francisco,
California
| $8K | – | – | – |
|
|
EDRH
32
Edmond de Rothschild Holding
Chambesy,
Switzerland
| $6K | -$491K | -36 | Closed |
|
|
TRCT
33
Tower Research Capital (TRC)
New York
| $6K | – | – | – |
|
|
LCM
34
Laurion Capital Management
New York
| – | -$532K | -42 | Closed |
|
35
PNC Financial Services Group
Pittsburgh,
Pennsylvania
| – | -$424K | -33 | Closed |
|
36
Millennium Management
New York
| – | -$262K | -21 | Closed |
|
37
Renaissance Technologies
New York
| – | -$244K | -19 | Closed |
|
38
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| – | -$225K | -18 | Closed |
|
|
IA
39
IFP Advisors
Tampa,
Florida
| – | -$1K | – | – |
|
INDP Hedge Fund Activity: Q4 2018 in Review
30 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Indaptus Therapeutics (INDP) for Q4 2018, worth a combined $90.1M — up 25% from $72.2M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new INDP positions and 6 closed out — a net gain of 5 holders — while 2 added to existing stakes and 13 trimmed.
The largest buyer was Essex Investment Management, opening a new position worth an estimated $2.4M. The largest seller was Prosight Management, cutting an estimated $4.02M.
- 30 institutional investors held Indaptus Therapeutics (INDP) as of Q4 2018, up from 25 in Q3 2018.
- Funds reported $90.1M of Indaptus Therapeutics stock for Q4 2018, up 25% quarter-over-quarter.
- 11 funds opened new Indaptus Therapeutics positions in Q4 2018 and 6 closed out, a net change of +5 holders.
- The largest Indaptus Therapeutics buyer in Q4 2018 was Essex Investment Management, an estimated $2.4M added.
- The largest Indaptus Therapeutics seller in Q4 2018 was Prosight Management, an estimated $4.02M sold.
Based on aggregated 13F filings for Q4 2018.